Literature DB >> 18538264

Exocrine pancreatic cancer clinical factors were related to timing of blood extraction and influenced serum concentrations of lipids.

Miquel Porta1, Olga Ferrer-Armengou, José Pumarega, Tomàs López, Marta Crous-Bou, Juan Alguacil, Montserrat Fitó, Manuel Jariod, Angel Vicente, Eva Morales, María-Isabel Covas, Elisa Puigdomènech, Nikhil Gupta.   

Abstract

OBJECTIVE: Disease-induced changes in blood concentrations of lipids may bias etiologic studies. We analyzed the influence of clinical factors and timing of blood extraction on serum concentrations of cholesterol and triglycerides in exocrine pancreatic cancer (EPC). STUDY DESIGN AND
SETTING: Subjects were 144 incident cases of EPC prospectively recruited in five teaching hospitals in eastern Spain.
RESULTS: Higher concentrations of cholesterol, triglycerides, and total lipids were observed among patients with a shorter interval from first symptom of cancer to blood extraction (IES); but concentrations were lower in patients with longer IES. The relationship between cholesterol and tumor stage was "n-shaped." Jaundice and other components of the cholestatic syndrome increased cholesterol and triglycerides. Invasive diagnostic tests were associated with lower cholesterol. All these factors were related to changes >50mg/dl in cholesterol (P<0.05), even when adjusting by stage. Statistical models including IES, number of invasive diagnostic tests, jaundice, weight loss, and stage explained over 28% of the variation in lipid concentrations.
CONCLUSION: Restriction and adjustment by stage may be insufficient to prevent biases related to disease progression. Multivariate analyses may allow to control to some extent the influence of clinical symptoms, procedures, and timing of blood extraction in studies on the etiological significance of lipids and lipophilic compounds, either risk factors or protective agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538264     DOI: 10.1016/j.jclinepi.2007.08.013

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  5 in total

1.  Timing of blood extraction in epidemiologic and proteomic studies: results and proposals from the PANKRAS II Study.

Authors:  Miquel Porta; José Pumarega; Olga Ferrer-Armengou; Tomàs López; Joan Alguacil; Núria Malats; Esteve Fernàndez
Journal:  Eur J Epidemiol       Date:  2007-07-18       Impact factor: 8.082

2.  Adjusting serum concentrations of organochlorine compounds by lipids and symptoms: a causal framework for the association with K-ras mutations in pancreatic cancer.

Authors:  Tomàs López; José A Pumarega; Anna Z Pollack; Duk-Hee Lee; Lorenzo Richiardi; David R Jacobs; Enrique F Schisterman; Miquel Porta
Journal:  Chemosphere       Date:  2014-05-20       Impact factor: 7.086

3.  Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients.

Authors:  Lucy A Parker; Miquel Porta; Blanca Lumbreras; Tomàs López; Luisa Guarner; Ildefonso Hernández-Aguado; Alfredo Carrato; Josep M Corominas; Juli Rifà; Esteve Fernandez; Joan Alguacil; Núria Malats; Francisco X Real
Journal:  Eur J Epidemiol       Date:  2011-02-06       Impact factor: 8.082

4.  Methodological deficits in diagnostic research using '-omics' technologies: evaluation of the QUADOMICS tool and quality of recently published studies.

Authors:  Lucy A Parker; Noemí Gómez Saez; Blanca Lumbreras; Miquel Porta; Ildefonso Hernández-Aguado
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

5.  Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma.

Authors:  Miquel Porta; José Pumarega; André F S Amaral; Jeanine M Genkinger; Judit Camargo; Lorelei Mucci; Juan Alguacil; Magda Gasull; Xuehong Zhang; Eva Morales; Mar Iglesias; Shuji Ogino; Lawrence S Engel
Journal:  Environ Res       Date:  2020-06-11       Impact factor: 6.498

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.